A Phase 1 interventional study of Ramucirumab and Docetaxel in Breast Cancer and Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 4 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 76th largest by enrollment of the 80 interventional ones that give a count, is the only one that started in 2010, is one of 17 in phase 1, and was the 41st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, France and 4 more countries
Ages 18+ · Women only
Eli Lilly and Company · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, China, Germany and 2 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 20 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 16 · Phase 4 4
First in 1998; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 138 across the 80 interventional studies. Of the 61 that completed or were terminated, 40 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Breast Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05514054Phase 3Eli Lilly and CompanyA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to investigate the safety and tolerability of the anti-VEGFR-2 monoclonal antibody ramucirumab drug product in combination with docetaxel in Japanese participants with metastatic, or locally advanced breast cancer, with the aim of confirming the recommended dose of ramucirumab drug product (DP) in combination with docetaxel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Ramucirumab · Drug: Docetaxel
Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
Also known as: IMC-1121B, LY3009806
Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m\^2) every 3 weeks.
Number of Participants With Adverse Events
Number participants with drug related dose-limiting toxicities (DLT) during Cycle 1; ramucirumab related: treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or higher TEAE, or TEAE leading to discontinuation or ramucirumab dose modification. DLT=G4 neutropenia \>7days; G ≥3 neutropenia with fever ≥38.5°C requiring IV antibiotics or bacteriemia or sepsis; G4 thrombocytopenia; G ≥3 thrombocytopenia with bleeding requiring platelets; G≥3 prothrombin time and/or partial thromboplastin time in absence of anticoagulants; G≥2 hyperbilirubinemia ≥5 days; QTc \>500 milliseconds (ms) or increase ≥100 ms or arrhythmia; G≥4 or uncontrollable hypertension; G≥3 nonhematologic toxicity (excluding G3: hypersensitivity, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea without loperamide therapy, nausea/vomiting without antiemetics, transient G3/4 elevation of aminotransferases); treatment delay \>2 weeks due to toxicity.
Time frame: Baseline up to data cut off (approximately 48.3 weeks)
Serum Anti-IMC-1121B Antibody Assessment (Immunogenicity)
The number of participants with a positive anti-IMC-1121B titer at any point during the study.
Time frame: Baseline up to data cut off (approximately 48.3 weeks)
Maximum Concentration (Cmax) of Ramucirumab
Cmax (Cycle 1) and Cmax at steady state (Cmax,ss, Cycle 4) of ramucirumab are provided.
Time frame: Day 1 of Cycle 1 and Cycle 4 (cycle=21 days)
Area Under the Curve (AUC) of Ramucirumab
AUC from time zero to infinity (AUC\[0-inf\], Cycle 1) and at steady state (AUC tau, Cycle 4) of ramucirumab are provided.
Time frame: Day 1 of Cycles 1 and 4 (cycle=21 days)
Half Life (t 1/2) of Ramucirumab
Time frame: Day 1 of Cycles 1 and 4 (cycle=21 days)
Clearance (Cl) of Ramucirumab
Clearance (Cycle 1) and at steady state (Clss, Cycle 4) of ramucirumab are provided.
Time frame: Day 1 of Cycle 1 and Cycle 4 (cycle=21 days)
Steady State Volume of Distribution (Vss) of Ramucirumab
Time frame: Day 1 of Cycle 1 and 4 (cycle=21 days)
| Milestone | Ramucirumab and Docetaxel Combination |
|---|---|
| Started | 7 |
| Received at least 1 dose of study drug | 7 |
| Completed | 6 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Number participants with drug related dose-limiting toxicities (DLT) during Cycle 1; ramucirumab related: treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or higher TEAE, or TEAE leading to discontinuation or ramucirumab dose modification. DLT=G4 neutropenia \>7days; G ≥3 neutropenia with fever ≥38.5°C requiring IV antibiotics or bacteriemia or sepsis; G4 thrombocytopenia; G ≥3 thrombocytopenia with bleeding requiring platelets; G≥3 prothrombin time and/or partial thromboplastin time in absence of anticoagulants; G≥2 hyperbilirubinemia ≥5 days; QTc \>500 milliseconds (ms) or increase ≥100 ms or arrhythmia; G≥4 or uncontrollable hypertension; G≥3 nonhematologic toxicity (excluding G3: hypersensitivity, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea without loperamide therapy, nausea/vomiting without antiemetics, transient G3/4 elevation of aminotransferases); treatment delay \>2 weeks due to toxicity.
| participants | Ramucirumab and Docetaxel Combination |
|---|---|
| Dose Limiting Toxicity (DLT) during Cycle 1 | 2 |
| TEAE related to ramucirumab | 7 |
| SAE related to ramucirumab | 4 |
| TEAE of Grade ≥3 related to ramucirumab | 6 |
| TEAE resulting in ramucirumab discontinuation | 3 |
| TEAE with ramucirumab dose modification/delay | 5 |
The number of participants with a positive anti-IMC-1121B titer at any point during the study.
| participants | Ramucirumab and Docetaxel Combination |
|---|---|
| Serum Anti-IMC-1121B Antibody Assessment (Immunogenicity) | 0 |
Cmax (Cycle 1) and Cmax at steady state (Cmax,ss, Cycle 4) of ramucirumab are provided.
| micrograms per milliliter (mcg/mL) | Ramucirumab and Docetaxel Combination |
|---|---|
| Cmax at Cycle 1 | 261 ± 22 |
| Cmax,ss at Cycle 4 (n=6) | 335 ± 22 |
AUC from time zero to infinity (AUC\[0-inf\], Cycle 1) and at steady state (AUC tau, Cycle 4) of ramucirumab are provided.
| micrograms*day/milliliter (mcg*day/mL) | Ramucirumab and Docetaxel Combination |
|---|---|
| AUC(0-inf) at Cycle 1 | 1700 ± 25 |
| AUC tau at Cycle 4 (n=6) | 2320 ± 24 |
| days | Ramucirumab and Docetaxel Combination |
|---|---|
| t1/2 at Cycle 1 | 6.57 ± 49 |
| t1/2 at Cycle 4 (n=6) | 11.9 ± 26 |
Clearance (Cycle 1) and at steady state (Clss, Cycle 4) of ramucirumab are provided.
| milliliters per hour (mL/hr) | Ramucirumab and Docetaxel Combination |
|---|---|
| Clearance at Cycle 1 | 13.6 ± 24 |
| Clearance at steady state (Clss) at Cycle 4 (n=6) | 10.2 ± 24 |
| liters (L) | Ramucirumab and Docetaxel Combination |
|---|---|
| Vss at Cycle 1 | 2.96 ± 32 |
| Vss at Cycle 4 (n=6) | 3.92 ± 18 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ramucirumab and Docetaxel Combination | — | 7/7 (100%) | 7/7 (100%) |
| Event | Ramucirumab and Docetaxel Combination |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/7 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/7 |
| Cardiac failureCardiac disorders | 1/7 |
| Neutrophil count decreasedInvestigations | 1/7 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/7 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/7 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 1/7 |
| Event | Ramucirumab and Docetaxel Combination |
|---|---|
| Oedema peripheralGeneral disorders | 7/7 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 6/7 |
| AlopeciaSkin and subcutaneous tissue disorders | 6/7 |
| NasopharyngitisInfections and infestations | 5/7 |
| Neutrophil count decreasedInvestigations | 5/7 |
| Nail disorderSkin and subcutaneous tissue disorders | 5/7 |
| Face oedemaGeneral disorders | 4/7 |
| MalaiseGeneral disorders | 4/7 |
| Mucosal inflammationGeneral disorders | 4/7 |
| DysgeusiaNervous system disorders | 4/7 |
| Age, Customized(participants) | Ramucirumab and Docetaxel Combination |
|---|---|
| Between 20 and 65 years | 6 |
| >=65 years | 1 |
| Sex: Female, Male(Participants) | Ramucirumab and Docetaxel Combination |
|---|---|
| Female | 7 |
| Male | 0 |
| Race/Ethnicity, Customized(participants) | Ramucirumab and Docetaxel Combination |
|---|---|
| Asian | 7 |
| American Indian or Alaska Native | 0 |
| Black or African American | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| White | 0 |
| Other | 0 |
| Region of Enrollment(participants) | Ramucirumab and Docetaxel Combination |
|---|---|
| Japan | 7 |
The record gives a start of Dec 2010, a primary completion of Nov 2012 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab